Patents by Inventor Marie Labus

Marie Labus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies against loricrin
    Patent number: 12455289
    Abstract: The present invention relates inter alia to the development of monoclonal antibodies against Loricrin and methods for determining whether a subject with melanoma has an increased risk of metastasis using said antibodies.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: October 28, 2025
    Assignee: AMLO Biosciences Limited
    Inventors: Penny Lovat, Marie Labus, Rob Ellis, Ashleigh McConnell
  • Monoclonal antibodies against Ambra-1
    Patent number: 12275780
    Abstract: The present invention relates inter alia to the development of monoclonal antibodies against Ambra-1 and methods for determining whether a subject with melanoma has an increased risk of metastasis using said antibodies.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: April 15, 2025
    Assignee: AMLO Biosciences Limited
    Inventors: Penny Lovat, Marie Labus, Rob Ellis, Ashleigh McConnell
  • BIOMARKERS FOR DISEASE PROGRESSION IN SQUAMOUS CELL CARCINOMA
    Publication number: 20220308059
    Abstract: The present invention relates inter alia to methods for determining whether a subject with squamous cell carcinoma (SCC) has an increased risk of metastasis. The invention further relates to methods of treating such subjects, diagnostic assays and kits. In certain embodiments, the invention relates to identifying whether a subject suffering from SCC has an increased risk of metastasis by determining the expression of Ambra-1 and p62 in a SCC tissue sample obtained from the subject.
    Type: Application
    Filed: May 1, 2020
    Publication date: September 29, 2022
    Inventors: Marie LABUS, Penny LOVAT, Rob ELLIS, Ashleigh MCCONNELL
  • MONOCLONAL ANTIBODIES AGAINST LORICRIN
    Publication number: 20210396758
    Abstract: The present invention relates inter alia to the development of monoclonal antibodies against Loricrin and methods for determining whether a subject with melanoma has an increased risk of metastasis using said antibodies.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 23, 2021
    Inventors: Penny LOVAT, Marie LABUS, Rob ELLIS, Ashleigh MCCONNELL
  • MONOCLONAL ANTIBODIES AGAINST AMBRA-1
    Publication number: 20210324059
    Abstract: The present invention relates inter alia to the development of monoclonal antibodies against Ambra-1 and methods for determining whether a subject with melanoma has an increased risk of metastasis using said antibodies.
    Type: Application
    Filed: November 4, 2019
    Publication date: October 21, 2021
    Inventors: Penny LOVAT, Marie LABUS, Rob ELLIS, Ashleigh MCCONNELL
  • Ambra-1 and Loricrin as biomarkers for disease progression in melanoma
    Patent number: 10634678
    Abstract: The present invention relates inter alia to therapeutic agents for use in the treatment of melanoma, methods of diagnosing an increased risk of metastasis in a subject suffering from melanoma, methods of treating such subjects, diagnostic assays and kits. More particularly, in certain embodiments the invention relates to identifying whether a subject suffering from melanoma has an increased risk of metastasis by determining the expression of Ambra-1 and Loricrin in a tissue sample obtained from the subject.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 28, 2020
    Assignee: AMLO Biosciences Limited
    Inventors: Marie Labus, Penny Lovat, Robert Ellis
  • BIOMARKERS FOR DISEASE PROGRESSION IN MELANOMA
    Publication number: 20200018756
    Abstract: The present invention relates inter alia to therapeutic agents for use in the treatment of melanoma, methods of diagnosing an increased risk of metastasis in a subject suffering from melanoma, methods of treating such subjects, diagnostic assays and kits. More particularly, in certain embodiments the invention relates to identifying whether a subject suffering from melanoma has an increased risk of metastasis by determining the expression of Ambra-1 and Loricrin in a tissue sample obtained from the subject.
    Type: Application
    Filed: July 30, 2019
    Publication date: January 16, 2020
    Inventors: Marie Labus, Penny Lovat, Robert Ellis
  • BIOMARKERS FOR DISEASE PROGRESSION IN MELANOMA
    Publication number: 20180196050
    Abstract: The present invention relates inter alia to therapeutic agents for use in the treatment of melanoma, methods of diagnosing an increased risk of metastasis in a subject suffering from melanoma, methods of treating such subjects, diagnostic assays and kits. More particularly, in certain embodiments the invention relates to identifying whether a subject suffering from melanoma has an increased risk of metastasis by determining the expression of Ambra-1 and Loricrin in a tissue sample obtained from the subject.
    Type: Application
    Filed: November 5, 2015
    Publication date: July 12, 2018
    Inventors: Marie Labus, Penny Lovat, Robert Ellis